Valuation: Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Market Cap 1.27TCr 187.09Cr 163.56Cr 150.31Cr 140.1Cr 265.74Cr 18TCr 269.77Cr 1.8TCr 701.49Cr 8.76TCr 702.27Cr 687.19Cr 30TCr P/E 2026 *
16.5x
P/E 2027 * 14x
Enterprise Value 1.13TCr 166.07Cr 145.18Cr 133.42Cr 124.36Cr 235.88Cr 16TCr 239.46Cr 1.6TCr 622.66Cr 7.77TCr 623.36Cr 609.98Cr 27TCr EV / Sales 2026 *
1.95x
EV / Sales 2027 * 2.13x
Free-Float
14.54%
Yield 2026 *
0.73%
Yield 2027 * 0.84%
26/05 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Ordinary Final Dividend on A Shares for the Year Ended December 31, 2025, Payable on 18 June 2026 CI
22/05 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Announces Board Changes CI
30/04 Shenzhen Hepalink Pharmaceutical's Profit Rises 20% in Q1 MT
29/04 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
30/03 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Proposes Final Ordinary Cash Dividend for the Year Ended 31 December 2025, Payable on 22 July 2026 CI
30/03 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
30/01 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2025 CI
30/01 Shenzhen Hepalink Forecasts Up to 56% Lower Profit in 2025 MT
16/12 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves the Election of Pu Hong as Independent Non-Executive Director, Effective December 16, 2025 CI
24/11 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Approves Retirement of Chuan Lu from the Board CI
30/25/30 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
29/25/29 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
18/25/18 Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Completes the First Subject and the First Dosing in the Phase 1 Clinical Trial CI
1 day+1.60%
1 week+10.40%
Current month+6.35%
1 month-0.83%
3 months-15.78%
6 months-21.07%
Current year-19.00%
1 week 8.69
Extreme 8.69
9.6
1 month 8.5
Extreme 8.5
9.74
Current year 8.5
Extreme 8.5
12.64
1 year 8.5
Extreme 8.5
14.34
3 years 6.89
Extreme 6.89
14.34
5 years 6.89
Extreme 6.89
18.89
10 years 6.89
Extreme 6.89
30.69
Manager TitleAgeSince
Chief Executive Officer 65 21/04/1998
Corporate Officer/Principal 61 21/04/1998
Director of Finance/CFO 51 21/08/2023
Director TitleAgeSince
Director/Board Member 61 21/04/1998
Director/Board Member 76 22/05/2023
Director/Board Member 69 16/05/2014
Date Insider Type Main position Quantity % Market Cap.
23/23/23Sell 11,200 0.0009%
26/21/26Other

Chief Financial Officer

4,59,588 0.2088%
Change 5-day change 1-year change 3-year change Capi.($)
+1.60%+10.40%-20.75%-18.10% 187.09Cr
+1.86%+0.48%+55.50%+160.66% 1,08200Cr
+3.57%+3.29%+68.60%+61.56% 63TCr
+3.99%+3.05%+37.93%+89.70% 46TCr
+0.32%+1.37%+31.00%+23.05% 34TCr
+0.19%+0.96%+39.86%+36.12% 30TCr
+0.50%+1.30%+30.37%+43.79% 29TCr
+1.08%+4.56%-25.37%-39.15% 22TCr
+3.55%+4.41%+25.45%+65.64% 20TCr
+4.21%+2.65%+17.47%+69.95% 16TCr
Average +2.11%+4.40%+26.01%+49.32% 36.94TCr
Weighted average by Cap. +2.21%+5.43%+41.85%+81.64%

Financials

2026 *2027 *
Net sales 577.55Cr 85Cr 74Cr 68Cr 64Cr 120.85Cr 8.1TCr 122.69Cr 820.66Cr 319.03Cr 3.98TCr 319.38Cr 312.53Cr 14TCr 627.47Cr 92Cr 81Cr 74Cr 69Cr 131.3Cr 8.8TCr 133.29Cr 891.59Cr 346.6Cr 4.33TCr 346.99Cr 339.54Cr 15TCr
Net income 86Cr 13Cr 11Cr 10Cr 9.46Cr 18Cr 1.2TCr 18Cr 121.89Cr 47Cr 591.49Cr 47Cr 46Cr 2.04TCr 100Cr 15Cr 13Cr 12Cr 11Cr 21Cr 1.4TCr 21Cr 141.91Cr 55Cr 688.63Cr 55Cr 54Cr 2.37TCr
Net Debt -142.7Cr -21Cr -18Cr -17Cr -16Cr -30Cr -2TCr -30Cr -202.76Cr -79Cr -983.93Cr -79Cr -77Cr -3.39TCr 67Cr 9.84Cr 8.6Cr 7.9Cr 7.37Cr 14Cr 936.66Cr 14Cr 95Cr 37Cr 460.42Cr 37Cr 36Cr 1.59TCr
Logo Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company primarily engaged in the heparin industry chain, contract development and manufacturing organization (CDMO) of biological macromolecules, and the investment, development, and commercialization of innovative drugs. The Company operates four segments. The Pharmaceutical Formulations segment manufactures and sells enoxaparin sodium injection and others. The Active Pharmaceutical Ingredients (APIs) segment manufactures and sells standard heparin APIs, enoxaparin APIs and others. The CDMO segment provides process development services for pharmaceutical intermediates and APIs, including process research, optimization, analytical testing, and formulation research. The Other segment engages in other product businesses, such as pancreatic enzymes and casings. The Company conducts its business in the domestic and overseas markets.
Employees
2,150
Date Price Change Volume
03/26/03 CN¥9.550 +1.60% 61,16,720
02/26/02 CN¥9.400 +1.18% 61,62,966
01/26/01 CN¥9.290 +3.45% 74,51,920
30/26/30 CN¥8.980 -2.29% 76,46,319
29/26/29 CN¥9.190 +6.24% 68,28,571
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
9.550CNY
Average target price
8.500CNY
Spread / Average Target
-10.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 002399 Stock